MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorder prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in a real-life clinical setting.
Currently, there is no recommendation on next-step treatment strategy if the patients remain suffering from residual symptoms, have incomplete remission, or have acute exacerbation of schizophrenia whilst receiving aripiprazole long acting injection at its recommended (maximum) dose, except to switch to other second generation antipsychotics (SGA) or to clozapine if they are in their treatment-resistant course. Such practice may incur risks of full relapse and/or unnecessary side effects to the patients, in particularly to those already showed insufficient treatment response, intolerability to side effects, or non-adherence to other antipsychotics before. On the contrary, adding another SGAs to this special cohort appears to be rational. Especially, brexpiprazole might be an ideal choice for its serotonin-dopamine activity modulator property to achieve better symptom control, and at the same time retaining the benefits from the lower incidence of side effects than other SGAs. Cases reports on combination therapy with aripiprazole (oral or LAI) with brexpiprazole had demonstrated initial favorable outcomes, albeit lacking empirical evidence from randomized controlled trial or longer term follow-up study. Therefore, the current MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorders prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in an non-interventional, naturalistic real-life clinical setting.
Study Type
OBSERVATIONAL
Enrollment
10
subject already receiving the combination of Abilify Maintena and Rexulti
subject already receiving the combination of Abilify Maintena and Rexulti
Queen Mary Hospital
Hong Kong, Hong Kong
RECRUITINGChange from baseline score of the Brief Psychiatric Rating Scale-24 at 3rd and 6th months
Measuring efficacy on positive and negative psychotic symptoms with a total score ranges from 24 (normal) to 168 (severe ill)
Time frame: 6 months
Change from baseline score of the Clinical Global Impression Scale at 3rd and 6th months
measuring efficacy on overall clinical improvement and severity of subjects with a score ranges from 0 (normal) to 18 (severely ill)
Time frame: 6 months
Change from baseline score of the Hamilton Anxiety Rating Scale at 3rd and 6th months
measuring anxiety symptoms of the subjects with a score ranges from 0 (not ill) to 56 (severe)
Time frame: 6 months
Change from basline score of the Hamilton Depression Rating Scale at 3rd and 6th months
measuring depressive symptoms of the subjects with a score ranges from 0 (normal) to 62 (very severe)
Time frame: 6 months
Change from basline score of the Simpson Angus Score at 3rd and 6th months
for intolerability assessment on extra-pyramidal side effects of the subjects from 0 (not present) to 24 (most severe)
Time frame: 6 months
Change from baseline score of the Barnes Akathisia Rating Scale at 3rd and 6th months
for intolerability assessment on akathisia of the subjects from 0 (not present) to 14 (severe)
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.